Glenmark's first clinical candidate targeting oncology indications
Glenmark Pharmaceuticals announced the its subsidiary Glenmark Pharmaceuticals S.A. (GPSA) has entered oncology with the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.GBR 1302 was discovered and developed by Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 1302 is based on Glenmark's innovative BEAT antibody technology platform.
Glenmark expects to obtain approval for the initiation of clinical studies during this financial year.
Powered by Capital Market - Live News
